期刊文献+

抗糖尿病药物DPP-4抑制剂的临床应用进展 被引量:6

下载PDF
导出
摘要 据国际糖尿病联合会(International Diabetes Federation,IDF)在《DiabetesAtlas》第6版2014年更新的最新数据显示,全球糖尿病患者已达3.87亿,预计到2035年将上升到5.92亿。仅在2014年,全球约有500万人因糖尿病引起的疾病死亡。我国糖尿病患者总数已达9628.8万,并以每年9.32%的发病率增长,成为世界第一糖尿病大国。
出处 《重庆医学》 CAS 北大核心 2016年第19期2706-2708,共3页 Chongqing medicine
基金 重庆医药高等专科学校科研计划项目(ygz2014107)
  • 相关文献

参考文献21

  • 1International Diabetes Federation. IDF Diabetes Atlas~R/ OL~. 6th ed. IDF,2013. E2016-05-30]. http://www, dia- betesatlas, org/resourees/previous-editions, html.
  • 2Association American Diabetes. Standards of medical care in diabetes-2015EJ~. Diabetes Care, 2015,38 ( 11 ) : 1 2.
  • 3Inzueehi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study o{ Diabetes (EASD) EJ ]. Diabetologia, 2012,55 ( 6 ) : 1577 1596.
  • 4伊遥.DPPIV抑制剂的幸福时光[N].医药经济报,201208—3l[2016—05—30].http://www.yyjjb.com.cn/html/201208/31/content—175209.htm.
  • 5Verspohl EJ. Novel therapeutics for type 2 diabetes., in- cretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase 4 inhibitors[J~. Phar macol Ther,2009,124(1) ..113 138.
  • 6Thornberry NA, Gallwitz B. Mechanism of action of in- hibitors of dipeptidyl-peptidase 4 (DPP-4)EJ~. Best Pract Res Clin Endocrinol Metab,2009,23(4)..479-486.
  • 7Feng J,Zhang Z, Wallace MB, et al. Discovery of aloglip- tin : a potent, selective, bioavailable, and efficacious inhibi- tor of dipeptidyl peptidase IV [J]. J Med Chem, 2007,50 (10) .-2297-2300.
  • 8Burkey BF, Hoffmann PK, Hassiepen U, et al. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in ro dents revisited[J~. Diabetes Obes Metab, 2008,10 ( 11 ) : 1057 1061.
  • 9Ahr~n B, Schweizer A,Dejager S, et al. Mechanisms of ac tion of the dipeptidyl peptidase-4 inhibitor vildagliptin in humansl-J~. Diabetes Obes Metab,2011,13(9):775-783.
  • 10Kim YB,Kopcho LM,Kirby MS,et al. Mechanism of Gly- Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin ( BMS-477118) EJ 1. Arch Biochem Biophys,2006,445(1) :9 18.

二级参考文献16

  • 1Federation International Diabetes,IDF Diabetes Atlas[M].6th ed.2013:Brussels,Belgium:International Diabetes Federation.
  • 2Association American Diabetes,Standards of Medical Care in Diabetes—2015[J].Diabetes Care,2015,38(Suppl1):S1-S2.
  • 3Deacon C F.Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes:a comparative review[J].Diabetes Obes Metab,2011.13(1):7-18.
  • 4Baetta R,Corsini A.Pharmacology of dipeptidyl peptidase-4inhibitors:similarities and differences[J].Drugs,2011.71(11):1441-1467.
  • 5Scheen A J,Paquot N.Gliptin versus a sulphonylurea as add-on to metformin[J].Lancet,2012,380(9840):450-452.
  • 6Esposito K,Chiodini P,Capuano A,et al.Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors:metaregression analysis of 78 randomized controlled trials with 20,053patients[J].Endocrine,2014,46(1):43-51.
  • 7Scirica B M,Bhatt D L,Braunwald E,et al.Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus[J].N Engl J Med,2013,369(14):1317-1326.
  • 8White W B,Cannon C P,Heller S R,et al.Alogliptin after acute coronary syndrome in patients with type 2 diabetes[J].N Engl J Med,2013,369(14):1327-1335.
  • 9.Green J B,Bethel M A,Armstrong P W,et al.Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes[J].N Engl J Med,2015[Epub ahead of print].
  • 10Umpierrez G E,Gianchandani R,Smiley D,et al.Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes:a pilot,randomized,controlled study[J].Diabetes Care,2013,36(11):3430-3435.

共引文献6

同被引文献43

引证文献6

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部